Free Trial
NYSE:IQV

IQVIA Q1 2025 Earnings Report

IQVIA logo
$153.42 +2.32 (+1.54%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$158.24 +4.82 (+3.14%)
As of 05/2/2025 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA EPS Results

Actual EPS
N/A
Consensus EPS
$2.62
Beat/Miss
N/A
One Year Ago EPS
N/A

IQVIA Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.77 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

IQVIA Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

IQVIA Earnings Headlines

Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
See More IQVIA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IQVIA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IQVIA and other key companies, straight to your email.

About IQVIA

IQVIA (NYSE:IQV) engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

View IQVIA Profile

More Earnings Resources from MarketBeat